Krishna Institute of Medical Sciences (KIMS) — Board Meeting

📢 Key Event
CARE Ratings submitted monitoring report for KIMS ₹1,500 crore QIP

🔄 What Changed
₹1,086.49 crore utilized in Q1 FY27; ₹413.51 crore remains unutilized

🔮 What's Next
No forward guidance provided in the filing

💡 Investor Takeaway
Funds are being deployed as planned with no material deviations, but commingling raises governance questions.

KIMS disclosed CARE Ratings' monitoring report for its ₹1,500 crore QIP, confirming full utilization of funds across repayment, subsidiary investments, and general corporate purposes with no deviations. The report validates compliance with SEBI regulations and shows ₹1,086.49 crore spent by Q1 FY27, leaving ₹413.51 crore unutilized, partially deployed in money market funds. The company commingled proceeds in subsidiary accounts, raising transparency concerns.

📄 View Original Announcement (PDF)

📊 Stock Analysis — KIMS ✨ Ask AI About This

About Krishna Institute of Medical Sciences Limited (KIMS)

Healthcare · Healthcare Services · Listed on NSE

Market Cap: ₹30,476.58 Cr P/E: 80.3

View full KIMS stock details →

📡 Get AI alerts when KIMS files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track KIMS — Free

💡 Ask AI about this filing

"How will the remaining ₹413.51 crore be deployed by FY27?" "What is the expected impact on KIMS's debt reduction timeline?" "How does commingling of funds affect subsidiary financial reporting?"

Ask AI Free →

📊 More KIMS filings

See all KIMS filings →

🔥 Also filed on 3 August 2026

TEXRAIL Texmaco Rail & Engineering Limited Financial Results UNITDSPR United Spirits Limited Announcement TENNIND Tenneco Clean Air India Limited Annual Report NAZARA Nazara Technologies Limited Financial Results NOIDATOLL Noida Toll Bridge Company Limited Financial Results RBA Restaurant Brands Asia Limited Financial Results

View all today's announcements →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when KIMS files new disclosures

Track KIMS filings, board meetings, and corporate actions. Free email alerts at 5 PM.